Your Health, We Care
brigatinib is a reversible dual inhibitor of ALK and epidermal growth factor receptor (EGFR), with activity against various kinases including ALK, ROS1, insulin-like growth factor 1 receptor (IGF-1R), etc.
It exerts its effect by inhibiting ALK phosphorylation and activation of downstream signaling proteins, and has a significant inhibitory effect on ALK positive tumor cells.
